Daniel K. Hall‐Flavin

Author

Also Known As

D Hall-Flavin, D K Hall-Flavin, D. Hall-Flavin, D. K. Hall-Flavin, D.K. Hall-Flavin, Daniel Hall-Flavin, Daniel Hall‐Flavin, Daniel K Hall-Flavin, Daniel K. Hall-Flavin, Daniel K. Hall‐Flavin

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Mayo Clinic Mayo Clinic in Florida Mayo Clinic in Arizona WinnMed RIKEN Center for Integrative Medical Sciences

About

Daniel K. Hall‐Flavin is an author at Mayo Clinic specializing in medicine, psychiatry, and social sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	863
2	Health Sciences	2	2	121
3	Public Health	2	2	83
4	Arts	1	1	43
5	Education	1	1	43

Daniel K. Hall‐Flavin

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting Daniel K. Hall‐Flavin, Joel G Winner, Josiah D. Allen, Pharmacogenetics and Genomics	2013	202
Using a pharmacogenomic algorithm to guide the treatment of depression Daniel K. Hall‐Flavin, Joel G Winner, Josiah D. Allen, Translational Psychiatry	2012	178
The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response Joanna M. Biernacka, Katrin Sangkuhl, Gregory D. Jenkins, Translational Psychiatry	2015	139
TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics M Gupta, Drew Neavin, Duan Liu, Molecular Psychiatry GeneticsGenetic EpidemiologyPsychopharmacologyPharmacotherapySocial Sciences	2016	116
Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes C. Anthony Altar, Joseph Carhart, Josiah D. Allen, The Pharmacogenomics Journal PsychiatryClinical ValidityPsychotropic MedicationPharmacologyDepression	2015	111
Alcohol Craving as a Predictor of Relapse Terry D. Schneekloth, Joanna M. Biernacka, Daniel K. Hall‐Flavin, American Journal on Addictions Substance UseMental HealthRelapse PreventionHarm ReductionSubstance Use Disorders	2012	102
Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons Krishna C. Vadodaria, Yuan Ji, Michelle Skime, Molecular Psychiatry Altered Serotonergic CircuitryPsychiatryNeurophysiologyPsychotropic MedicationNeurotransmitter	2019	94
Validation of the 17‐item <scp>Hamilton Depression Rating Scale</scp> definition of response for adults with major depressive disorder using equipercentile linking to <scp>Clinical Global Impression</scp> scale ratings: analysis of <scp>Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study</scp> (PGRN‐AMPS) data William V. Bobo, Gabriela C. Angleró, Gregory D. Jenkins, Human Psychopharmacology Clinical and Experimental	2016	88
A retrospective study of gender differences in depressive symptoms and risk of relapse in patients with alcohol dependence Osama A. Abulseoud, Victor M. Karpyak, Terry D. Schneekloth, American Journal on Addictions	2013	84
Serotonin-induced hyperactivity in SSRI-resistant major depressive disorder patient-derived neurons Krishna C. Vadodaria, Yuan Ji, Michelle Skime, Molecular Psychiatry PsychiatryMedicinePsychotropic MedicationPsychopharmacologyDepression	2019	83

Page 1